NCT06450041 2026-03-23NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) TrialNew Approaches to Neuroblastoma Therapy ConsortiumPhase 2 Recruiting62 enrolled